Arcturus Therapeutics (ARCT) News Today $17.66 +0.74 (+4.37%) As of 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Arcturus Therapeutics price target raised to $48 from $41 at BTIGFebruary 18 at 10:42 AM | markets.businessinsider.comShort Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Declines By 9.9%Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,540,000 shares, a drop of 9.9% from the January 15th total of 5,040,000 shares. Approximately 18.5% of the company's stock are sold short. Based on an average daily trading volume, of 429,700 shares, the short-interest ratio is presently 10.6 days.February 17, 2025 | marketbeat.comEmpire Life Investments Inc. Raises Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Empire Life Investments Inc. increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 85.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 279,463 sharesFebruary 16, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from BrokeragesFebruary 16, 2025 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT)HC Wainwright reissued a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Friday.February 15, 2025 | marketbeat.comCSL, Arcturus Therapeutics announce European Commission approval for KostaiveFebruary 14, 2025 | markets.businessinsider.comArcturus Therapeutics and CSL’s Kostaive COVID-19 vaccine approved in EuropeFebruary 14, 2025 | markets.businessinsider.comBreaking Down Arcturus Therapeutics: 5 Analysts Share Their ViewsFebruary 14, 2025 | benzinga.comEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineFebruary 14, 2025 | prnewswire.comEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineFebruary 14, 2025 | businesswire.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Buy" by BrokeragesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average rating of "Buy" from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy ratFebruary 13, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Sumitomo Mitsui Trust Group Inc. decreased its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,065,050 shares of the biotechnology company's stock after sFebruary 12, 2025 | marketbeat.comArcturus Therapeutics appoints Moncef Slaoui as chair designateFebruary 4, 2025 | markets.businessinsider.comArcturus Therapeutics names Moncef Slaoui as Chair DesignateFebruary 4, 2025 | msn.comArcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair DesignateFebruary 4, 2025 | finance.yahoo.comShort Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Rises By 8.6%Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 31st total of 4,440,000 shares. Approximately 19.6% of the shares of the company are sold short. Based on an average daily volume of 400,900 shares, the days-to-cover ratio is currently 12.0 days.February 2, 2025 | marketbeat.comEd Arce’s Buy Rating on Arcturus Therapeutics Driven by Strategic Advancements and Strong Market PositioningJanuary 31, 2025 | markets.businessinsider.comMeiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19January 31, 2025 | businesswire.comH.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)January 29, 2025 | markets.businessinsider.comBTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy RecommendationJanuary 29, 2025 | msn.comArcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal yearJanuary 28, 2025 | msn.comArcturus: Downgrading As mRNA Promise Meets Market RealityJanuary 28, 2025 | seekingalpha.comArcturus Therapeutics initiated with a Buy at BTIGJanuary 28, 2025 | markets.businessinsider.comBTIG sets $41 target for Arcturus stock, cites strong prospectsJanuary 28, 2025 | msn.comDemystifying Arcturus Therapeutics: Insights From 5 Analyst ReviewsJanuary 28, 2025 | benzinga.comArcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated by Analysts at BTIG ResearchBTIG Research initiated coverage on shares of Arcturus Therapeutics in a report on Tuesday. They issued a "buy" rating and a $41.00 target price on the stock.January 28, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for ARCT FY2024 Earnings?Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings estimates for Arcturus Therapeutics in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo now forecasts that the biotechnology companJanuary 24, 2025 | marketbeat.comResearch Analysts Set Expectations for ARCT FY2025 EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Arcturus Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biotechnologJanuary 23, 2025 | marketbeat.comAnalysts Offer Predictions for ARCT Q3 EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Arcturus Therapeutics in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo forecasts that the biotechnology comJanuary 23, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Large Growth in Short InterestArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 15th total of 4,440,000 shares. Currently, 19.6% of the shares of the company are sold short. Based on an average trading volume of 400,900 shares, the short-interest ratio is currently 12.0 days.January 19, 2025 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Buy" from BrokeragesShares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has assignedJanuary 19, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Purchases 47,824 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Hennion & Walsh Asset Management Inc. boosted its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 139.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 82,057 shares of the biotechnology coJanuary 19, 2025 | marketbeat.comArcturus Therapeutics: Anticipated Growth through Innovative Therapies and Strategic TrialsJanuary 17, 2025 | markets.businessinsider.comArcturus Therapeutics Poised for Transformative Growth in 2025 with Promising Pipeline and Strategic AdvancementsJanuary 17, 2025 | markets.businessinsider.comBuy Rating for Arcturus Therapeutics Driven by Promising Vaccine Candidate and Strategic PartnershipsJanuary 13, 2025 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comArcturus Therapeutics initiates ARCT-2304 studyJanuary 10, 2025 | markets.businessinsider.comArcturus Therapeutics launches Phase I Avian Influenza trials in USJanuary 10, 2025 | finance.yahoo.comArcturus Therapeutics (ARCT) Initiated with a Buy at Piper SandlerJanuary 8, 2025 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 8.6% - Here's WhyArcturus Therapeutics (NASDAQ:ARCT) Trading Down 8.6% - Here's WhyJanuary 8, 2025 | marketbeat.comBuy Recommendation for Arcturus Therapeutics Amid Growing H5N1 Vaccine DemandJanuary 7, 2025 | markets.businessinsider.comArcturus Therapeutics: Strategic Advancements and Promising mRNA Pipeline Support Buy RatingJanuary 7, 2025 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% Higher - What's Next?Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 5.9% - Here's What HappenedJanuary 7, 2025 | marketbeat.comArcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday.January 7, 2025 | marketbeat.comGalectin Therapeutics (GALT) was downgraded to a Hold Rating at H.C. WainwrightDecember 27, 2024 | markets.businessinsider.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Increased by Franklin Resources Inc.Franklin Resources Inc. lifted its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 54.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 103,936 shares of the biotechnology company's stock afteDecember 27, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by BrokeragesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given an average recommendation of "Buy" by the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one hasDecember 25, 2024 | marketbeat.comHigh Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two OthersDecember 24, 2024 | finance.yahoo.comState Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)State Street Corp cut its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,472,955 shares of the biotechnology company'December 21, 2024 | marketbeat.comWe're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn RateDecember 20, 2024 | finance.yahoo.com Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.550.60▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼95▲ARCT Articles Average Week Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tarsus Pharmaceuticals News Janux Therapeutics News Agios Pharmaceuticals News NewAmsterdam Pharma News IDEAYA Biosciences News Schrödinger News Travere Therapeutics News Belite Bio News Vera Therapeutics News Iovance Biotherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts